Here we provided a critical review of the development history and status of OVT, emphasizing the mechanisms of enhancing both safety and efficacy. We propose that oncolytic virotherapy has evolved into the fourth generation as tumor immunotherapy. Particularly, to arouse T cells by designing OVs expressing bi-specific T cell activator (BiTA) is a promising strategy of killing two birds with one stone. Amazing combination of therapeutic strategies of OVs and immune cells confers immense potential for managing cancers. Moreover, the attractive preclinical OVT addressed recently, and the OVT in clinical trials were systematically reviewed.
OVs, which are advancing into clinical trials, are being envisioned as the frontier clinical anti-tumor agents coming soon.
方法:在这里,我们对OVT的发展历史和现状进行了严格的回顾,强调提高安全性和有效性的机制。我们认为溶瘤病毒疗法已经发展成为第四代肿瘤免疫疗法。特别是,通过设计表达双特异性T细胞激活剂(BiTA)的OV来激发T细胞是一种用一块石头杀死两只鸟的有希望的策略。OVs和免疫细胞的治疗策略的惊人组合赋予了管理癌症的巨大潜力。此外,最近讨论了有吸引力的临床前OVT,并对临床试验中的OVT进行了系统评价。
结论:OVs,正在进入临床试验,即将成为临床抗肿瘤药物的前沿。